List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development
Asklepion Pharmaceuticals LLC
AstraZeneca Plc
Bristol-Myers Squibb Co
Cyclerion Therapeutics Inc
Global Blood Therapeutics Inc
GlycoMimetics Inc
Hartis Pharma SA
KM Biologics Co Ltd
NicOx SA
Novartis AG
Prolong Pharmaceuticals LLC
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Drug Profiles
apadamtase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apixaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizanlizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HRT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-Citrulline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naproxcinod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olinciguat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivipansel sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ticagrelor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones
Featured News & Press Releases
Oct 05, 2020: FDA grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for treatment of sickle cell disease
Jun 12, 2020: New efficacy and biomarker data from Rivipansel phase 3 RESET trial to be presented at Sickle Cell meeting
Dec 20, 2019: Novartis wins Medicaid approval for new sickle cell drug in key US states
Nov 18, 2019: FDA approves Novartis' Adakveo for sickle cell disease patients
Aug 05, 2019: Pfizer's RESET trial of rivipansel fails to meet endpoints
Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
May 06, 2019: GlycoMimetics announces enrollment completed for phase 3 clinical trial evaluating Rivipansel in Sickle Cell Disease
Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting
Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology
Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Asklepion Pharmaceuticals LLC, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Cyclerion Therapeutics Inc, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by GlycoMimetics Inc, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Hartis Pharma SA, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by KM Biologics Co Ltd, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by NicOx SA, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Novartis AG, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, H2 2020
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products, H2 2020

List of Figures
Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• Asklepion Pharmaceuticals LLC
• AstraZeneca Plc
• Bristol-Myers Squibb Co
• Cyclerion Therapeutics Inc
• Global Blood Therapeutics Inc
• GlycoMimetics Inc
• Hartis Pharma SA
• KM Biologics Co Ltd
• NicOx SA
• Novartis AG
• Prolong Pharmaceuticals LLC